Pfizer (PFE) Share-based Compensation (2009 - 2026)

Pfizer (PFE) has reported Share-based Compensation for 18 consecutive years, with $249.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 22.66% year-over-year to $249.0 million in Q2 2026; TTM through Jun 2026 was -$1.1 billion, a 189.21% decrease from a year earlier, with the FY2025 full-year figure at -$1.3 billion, up 61.86% from the prior year.
• Share-based Compensation was $249.0 million for Q2 2026 at Pfizer, down from $272.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $700.0 million in Q3 2024 and troughed at -$1.9 billion in Q4 2025.
• A 5-year average of $88.8 million and a median of $204.5 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 72.19% in 2022 and soared 109.52% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $287.0 million in 2022, then dropped by 9.76% to $259.0 million in 2023, then surged by 170.27% to $700.0 million in 2024, then plunged by 366.14% to -$1.9 billion in 2025, then jumped by 113.37% to $249.0 million in 2026.
• The last three Share-based Compensation figures came in at $249.0 million (Q2 2026), $272.0 million (Q1 2026), and -$1.9 billion (Q4 2025), per Business Quant data.